English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/38500
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis

AuthorsPalacios, Carmen ; Martín-Pérez, Rosa ; López-Pérez, Ana Isabel ; Pandiella, Atanasio ; López-Rivas, Abelardo
Keywords3-MA
17DMAG
Apoptosis
Autophagy
Multiple myeloma
Issue DateNov-2010
PublisherElsevier
CitationLeukemia Research 34(11): 1533-1538 (2010)
AbstractThe Hsp90 inhibitor 17DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin) is currently undergoing clinical trials as an antitumor drug. We show here that treatment of human multiple myeloma (MM) cells with 17DMAG induces mTOR inhibition and microtubule-associated protein light chain 3 (LC3) conversion (LC3-I to LC3-II), an indicator of autophagy. Interestingly, 17DMAG synergistically induces apoptosis through a mitochondria-operated pathway in the presence of the autophagy inhibitor 3-methyladenine (3-MA). Inhibition of autophagy by 3-MA facilitated caspase activation, cytochrome c release from mitochondria and poly (ADP-ribose) polymerase (PARP) cleavage in myeloma cells treated with 17DMAG. The potential use of Hsp90 and autophagy inhibitors combinations as a therapeutic tool in MM is further discussed in our work.
Description6 páginas, 4 figuras.
Publisher version (URL)http://dx.doi.org/10.1016/j.leukres.2010.07.002
URIhttp://hdl.handle.net/10261/38500
DOI10.1016/j.leukres.2010.07.002
ISSN0145-2126
Appears in Collections:(CABIMER) Artículos
(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.